Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate sweeping drug recalls over issues pertaining to ...
In 2019, evidence showed that an impurity in drug degrades over time to form probable carcinogenic compound. Ranitidine is ...
At present, there is no proposal to prohibit the manufacture, distribution and sale of Ranitidine, a medication used to ...
The Indian government currently has no plans to ban Ranitidine, a stomach acid reducer, despite international concerns about impurities. Actions include testing and communication with drug ...
The FDA has been investigating NDMA and other nitrosamine impurities in blood pressure and heart failure medicines called angiotensin II receptor blockers or ‘sartans’ since last year ...
India’s Ministry of Health has taken no steps to stop other pharmaceutical companies from continuing to manufacture and sell ...
NDMA is classified as a probable human carcinogen ... Currently, there is no evidence that medicines containing this type of impurity have caused any harm to patients, say experts.
It follows concern in several countries over the presence of impurities in Zantac and other ... review the presence of N-nitrosodimethylamine (NDMA) in medicines containing the drug ranitidine.
The National Data Management Authority (NDMA) yesterday said that its cybersecurity team comprising Justino DaSilva, Shameer Jalim, Maryam Bacchus, Latoya Etkins, and Irshad Nasir achieved a ...